| Identification | Back Directory | [Name]
CAA-0225 | [CAS]
244072-26-2 | [Synonyms]
CAA-0225
(2S,3S)-2-N-[(2S)-1-(benzylamino)-1-oxo-3-phenylpropan-2-yl]-3-N-[2-(4-hydroxyphenyl)ethyl]oxirane-2,3-dicarboxamide | [Molecular Formula]
C28H29N3O5 | [MDL Number]
MFCD25976800 | [MOL File]
244072-26-2.mol | [Molecular Weight]
487.55 |
| Hazard Information | Back Directory | [Description]
CAA0225 is a novel inhibitor specific for cathepsin L. CAA0225 is a probe for autophagic proteolysis. | [Uses]
CAA-0225 is a tissue protease L inhibitor that inhibits rat liver tissue protease L with a IC50 value of 1.9 nM. CAA-0225 can participate in the degradation of autophagosome membrane markers LC3-II and GABARAP (HY-P72639), improve cardiac function in mice with reperfusion injury, and kill and eliminate Trypanosoma brucei parasites[1][2][3]. | [in vivo]
CAA-0225 (0.25 mg, i.v.) improves cardiac function and reduces infarct size by inhibiting the release of cardiac cathepsin L in a mouse model of reperfusion after myocardial infarction[2]. | Animal Model: | Model of reperfusion injury involved male C57Bl/6 mice aged 9–12?weeks[2]. | | Dosage: | 0.25 mg | | Administration: | Intravenous injection (i.v.) | | Result: | Reduced infarct size, improved systolic and diastolic cardiac function. |
| [IC 50]
cathepsin L | [References]
[1] Characterization of CAA0225, a Novel Inhibitor Specific for Cathepsin L, as a Probe for Autophagic Proteolysis |
|
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
|